Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.42 USD | +1.14% | -0.93% | -5.65% |
Apr. 17 | Sector Update: Health Care Stocks Mixed Wednesday Afternoon | MT |
Apr. 17 | Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise | MT |
Evolution of the average Target Price on Celldex Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Celldex Therapeutics, Inc.
TD Cowen | |
Wells Fargo Securities | |
HC Wainwright | |
Guggenheim | |
SVB Securities LLC | |
Jefferies & Co. | |
SVB Leerink |
EPS Revisions
- Stock Market
- Equities
- CLDX Stock
- Consensus Celldex Therapeutics, Inc.